Search PubMed⌕ Search

Biomedical subjects

K Helmke

Publications and source records attributed to K Helmke.

130 records · Page 8Linked to original sources

[Polymyalgia rheumatica and giant cell arteritis; diagnosis and side effects of low-dose long-term glucocorticoid therapy].

Due to good therapeutic results and few side-effects so-called "low-dose glucocorticoid therapy" (ldgc) with daily glucosteroid dosage below 10 mg prednisolone-equivalent has recently been recommended in managing polymyalgia rheumatica and giant cell arteritis. This fact is of important interest, since mean therapy time is often over a period of five years. An open-prospective study with 75 patients in a rheumatological unit was done in which different clinical histories were examined and glucosteroid side effects of 47 patients who had received therapy over six months were analyzed. Main side-effect shown was osteoporosis (n = 7), other known steroid-side effects were quite seldom (less than 5%). Dosage regimens and therapy monitoring criteria are proposed.

Aged↗

[Suppressor T cell function in undifferentiated collagenoses].

In order to study early cellular defects in connective tissue diseases, suppressor T-cell function in undifferentiated connective tissue syndromes was determined. The capacity of T8(CD8)-positive cells to suppress pokeweed mitogen-induced IgG and IgM secretion was studied in 14 patients. Compared with normals, a reduced activity of cells to suppress the IgM response was shown, whereas the suppression of IgG secretion was not affected.

Adult↗

[Standardization of specific laboratory methods within the framework of a therapeutic study of rheumatic diseases].

Immunological techniques and immunophenomena are acquiring an increasing significance in the diagnosis and control of rheumatic diseases. Alongside clinical, radiological, and biochemical investigations, they play an important role in the evaluation of a therapy and in the control of its benefits and side effects. It follows that immunological investigations and techniques should be taken into consideration when a multicenter trial is planned. However, this means that reproducible and thus comparable results must be obtained by the different laboratories participating in a multicenter therapeutic study. Exact standardization of the immunological test systems used is necessary, at least between the participants in the trial. Another critical point lies in the different clinical relevance and the distinct diagnostic value of the various immunophenomena and test systems. These differences must be strongly taken into account to minimize the effort and increase the effect of the investigations and the relevance of the results.

Clinical Trials as Topic↗